Camille L Bedrosian Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Camille L Bedrosian is EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 46,720 shares of RARE, which is worth approximately $1.92 Million. The most recent transaction as insider was on Mar 01, 2023, when has been sold 3,881 shares (Common Stock) at a price of $45.25 per share, resulting in proceeds of $175,615. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.7K

0% 3M change

0% 12M change

Total Value Held $1.92 Million

Camille L Bedrosian Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2023	SELL Open market or private sale	$175,615 $45.25 p/Share	3,881 Reduced 7.67%	46,720 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	2,663 Added 5.0%	50,601 Common Stock
Mar 01 2022	SELL Open market or private sale	$187,935 $66.62 p/Share	2,821 Reduced 7.67%	33,938 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	14,000 Added 22.6%	47,938 Common Stock
Jan 30 2022	SELL Open market or private sale	$109,859 $66.3 p/Share	1,657 Reduced 4.31%	36,759 Common Stock
Oct 14 2021	SELL Open market or private sale	$29,129 $81.14 p/Share	359 Reduced 0.93%	38,416 Common Stock
Sep 02 2021	SELL Open market or private sale	$250,450 $100.18 p/Share	2,500 Reduced 6.06%	38,775 Common Stock

Sep 02 2021	BUY Exercise of conversion of derivative security	$137,500 $55.0 p/Share	2,500 Added 5.71%	41,275 Common Stock
Sep 01 2021	SELL Open market or private sale	$250,075 $100.03 p/Share	2,500 Reduced 6.06%	38,775 Common Stock
Sep 01 2021	BUY Exercise of conversion of derivative security	$137,500 $55.0 p/Share	2,500 Added 5.71%	41,275 Common Stock
May 06 2021	SELL Open market or private sale	$41,376 $113.67 p/Share	364 Reduced 0.93%	38,775 Common Stock
Apr 15 2021	SELL Open market or private sale	$545,450 $109.09 p/Share	5,000 Reduced 11.33%	39,139 Common Stock
Apr 15 2021	BUY Exercise of conversion of derivative security	$275,000 $55.0 p/Share	5,000 Added 10.18%	44,139 Common Stock
Mar 01 2021	SELL Open market or private sale	$627,752 $138.18 p/Share	4,543 Reduced 10.4%	39,139 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	10,136 Added 18.83%	43,682 Common Stock
Jan 30 2021	SELL Open market or private sale	$314,827 $140.36 p/Share	2,243 Reduced 6.27%	33,546 Common Stock
Jan 15 2021	SELL Open market or private sale	$3,479,500 $139.18 p/Share	25,000 Reduced 41.13%	35,789 Common Stock
Jan 15 2021	BUY Exercise of conversion of derivative security	$1,375,000 $55.0 p/Share	25,000 Added 29.14%	60,789 Common Stock
Oct 14 2020	SELL Open market or private sale	$23,056 $88.0 p/Share	262 Reduced 0.73%	35,789 Common Stock

Also insider at

CRNX

Crinetics Pharmaceuticals, Inc. Healthcare

RYTM

RHYTHM PHARMACEUTICALS, INC. Healthcare

Director

AMLX

Amylyx Pharmaceuticals, Inc. Healthcare

Chief Medical Officer

CLB